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ABSTRACT
Objective To assess whether a combination of
adalimumab and ciprofloxacin is superior to adalimumab
alone in the treatment of perianal fistulising Crohn’s
disease (CD).
Design Randomised, double-blind, placebo controlled
trial in eight Dutch hospitals. In total, 76 CD patients with
active perianal fistulising disease were enrolled. After
adalimumab induction therapy (160/80 mg week 0, 2),
patients received 40 mg every other week together with
ciprofloxacin 500 mg or placebo twice daily for 12 weeks.
After 12 weeks, adalimumab was continued. Follow-up
was 24 weeks. Primary endpoint (clinical response) was
defined as 50% reduction of fistulas from baseline to week
12. Secondary endpoints included remission (closure of all
fistulas), Perianal Crohn’s Disease Activity Index, Crohn’s
Disease Activity Index (CDAI) and Inflammatory Bowel
Disease Questionnaire (IBDQ).
Results Clinical response was observed in 71% of
patients treated with adalimumab plus ciprofloxacin and in
47% treated with adalimumab plus placebo (p=0.047).
Likewise, remission rate at week 12 was significantly higher
(p=0.009) in the combination group (65%) compared with
adalimumab plus placebo (33%). Combination treatment
was associated with a higher mean CDAI change and
mean IBDQ change at week 12 (p=0.005 and p=0.009,
respectively). At week 24, no difference in clinical response
between the two treatment groups was observed
(p=0.22). No difference in safety issues was observed.
Conclusions Combination therapy of adalimumab and
ciprofloxacin is more effective than adalimumab
monotherapy to achieve fistula closure in CD. However,
after discontinuation of antibiotic therapy, the beneficial
effect of initial coadministration is not maintained.
Trial registration ClinicalTrials.gov Identifier:
NCT00736983.
BACKGROUND
Perianal fistulising disease occurs in up to 40% of
Crohn’s disease (CD) patients and its natural history
is characterised by chronicity with only rarely spon-
taneous healing of the fistula tracts.1 2 Perianal pro-
blems have a negative impact on the perceived health
related quality of life3 and despite intensive medical
and surgical treatment, a considerable percentage of
patients will continue to have debilitating perianal
symptoms. This ultimately leads to extensive surgery
such as proctocolectomy.2 4 Antibiotics are used for
fistulising CD and this is primarily based on uncon-
trolled data, demonstrating response with metronida-
zole in up to 83% of patients.5 A randomised trial
comparing metronidazole, ciprofloxacin and placebo
failed to show the superiority of antibiotic treatment,
largely ascribed to the relatively small sample size.6
Infliximab (antitumour necrosis factor (anti-TNF))
demonstrated to induce and maintain response in
patients with fistulising CD.7 8 The CHARM trial,
a randomised, placebo controlled trial investigating
the role of adalimumab, a fully humanised monoclo-
nal anti-TNF antibody, in CD, and in which the
Significance of this study
What is already known on this subject?
▸ Perianal fistulas are common in patients with
Crohn’s disease and negatively impact quality
of life.
▸ Spontaneous healing of fistula tracts seldom
occurs.
▸ Antitumour necrosis factor antibodies are
effective for the treatment of Crohn’s disease
related fistulas.
What are the new findings?
▸ Combination therapy of adalimumab and
ciprofloxacin results in a higher fistula closure
rate and results in a better quality of life than
adalimumab therapy alone.
▸ After discontinuation of ciprofloxacin the initial
beneficial effect on fistula closure is not
sustained.
▸ Previous administration of infliximab does not
influence the effect of adalimumab to induce
fistula closure.
How might it impact on clinical practice in
the foreseeable future?
▸ To induce fistula closure in patients with
perianal fistulising Crohn’s disease the
association of ciprofloxacin with adalimumab is
preferred over adalimumab alone.
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closure of fistulas was a secondary endpoint, documented that ada-
limumab induced a reduction in the mean number of draining fis-
tulas per day compared with placebo during a treatment period of
1 year.9 In the open-label extension study of the CHARM, 90% of
patients maintained response to fistula treatment after an add-
itional year of treatment with adalimumab.10
We previously demonstrated that combination therapy of
infliximab and ciprofloxacin was associated with a trend to
higher response compared with infliximab alone, suggesting that
anti-TNF treatment for fistulising CD combined with ciprofloxa-
cin is more effective than anti-TNF alone.11 Here, we report the
ADAFI trial (ADAlimumab for the treatment of perianal FIstulas
in Crohn’s disease) investigating combination therapy of adali-
mumab with ciprofloxacin or placebo in a randomised, con-
trolled fashion for the treatment of perianal fistulising CD.
METHODS
Study design and sample size
This multicentre, randomised, double-blind, placebo controlled
trial was designed to evaluate the efficacy and safety of combination
therapy of adalimumab and ciprofloxacin (ADA+CIP) in compari-
son with adalimumab and placebo (ADA+PLA) for the treatment
of CD related, active perianal fistulising disease (ClinicalTrials.gov
number NCT00736983). The ADAFI trial was conducted in
accordance with the protocol International Conference on
Harmonization Guidelines for Good Clinical Practice, the
Declaration of Helsinki and local national regulations governing
clinical study conduct. The protocol was approved by the institu-
tional review board or by the ethics committee at each centre. The
study was not designed for an interim analysis and no Data Safety
Monitoring Board was assigned. All patients gave written informed
consent. Patients were enrolled at eight sites in The Netherlands
from September 2008 to March 2011. The sample size calculation
was based on results from a small open-label study,12 at the time of
the study design presented in abstract form (Digestive Disease
Week 2006), reporting that adalimumab administration resulted in
64% of patients in closure of at least 50% of the number of drain-
ing fistulas. An absolute increment of 20% of patients reaching the
primary endpoint in the combination treatment arm was deemed
to be clinically relevant. Using the two-group χ2 test for equal pro-
portions and equal group size and with the power fixed to 80%
and a two-sided significance level of α=0.05, the sample size was
calculated to be 73 patients per group.
Intervention and randomisation
All patients received an induction regimen with 160 mg adali-
mumab at day 0 and 80 mg at week 2. At week 4, patients
received 40 mg adalimumab every other week until the end of
follow-up at week 24. Patients self-administered adalimumab by
subcutaneous injection as prescribed by the manufacturer.
Patients were randomly assigned to additionally receive cipro-
floxacin 500 mg or placebo twice daily from day 0 on for
12 weeks. Randomisation was performed through a centralised
randomisation schedule in a 1:1 ratio. Perianal setons, if
present, were removed at week 2.
Patients
Men and women diagnosed with CD and between 18 and
70 years of age with active fistulising perianal disease at
screening and baseline were included. Previous treatment with
infliximab was permitted if infliximab had been discontinued
at least 12 weeks before the screening visit and the patient
had initially experienced response to the agent (as judged by
the investigating physician). Baseline fistula data were noted.
Demographic and baseline CD severity data, concomitant
medication use, previous history of TNF-antagonist use and
smoking history were collected. The diagnosis of CD (at least
3 months in duration) was radiologically or endoscopically/
histologically confirmed. Women of childbearing potential
were required to use an effective form of birth control.
Concomitant use of thiopurine derivatives, methotrexate and
5-aminosalicylic acid was allowed provided the dose was
stable for at least 12 weeks. Oral corticosteroids were allowed
if patients initiated this treatment at least 4 weeks prior to
randomisation and if they were on a stable dose not above
20 mg/day of prednisone equivalent over the 2 weeks prior to
randomisation. From 6 weeks after randomisation of a
subject, it was advocated to taper corticosteroid treatment.
Use of antibiotics for CD within 3 months prior to random-
isation and a history of allergy to quinolones or previous
treatment with adalimumab were exclusion criteria.
Patients were also excluded if they had a history of lympho-
proliferative disease or cancer, other than skin basocellular
carcinoma; listeriosis; HIV infection; immunodeficiency syn-
drome; central nervous system demyelinating disease; chronic
hepatitis B or C virus infection; or untreated tuberculosis at
baseline. Patients were excluded if they had perianal abscesses;
renal insufficiency (elevated serum creatine), significant pul-
monary dysfunction, poorly controlled medical conditions,
including diabetes mellitus and unstable ischaemic heart
disease; a history of QT prolongation; a known pre-existing
condition that could interfere with the patient’s participation
such as psychiatric conditions, central nervous system trauma
or active seizure disorders. In addition, patients were excluded
if they had undergone treatment with any investigational
agent in the past 12 weeks or five half-lives prior to the
screening visit. Patients with a history of clinically significant
drug or alcohol abuse in the last 2 years were not allowed to
participate in this study.
Study endpoints
At baseline, week 12 and week 24, a dedicated, clinical examin-
ation of rectum and perineum with gentle compression of fistula
tracts was performed by a physician blinded for the treatment
allocation to assess the number of draining fistulas and to
exclude the presence of abscesses. Patients who did not have
draining fistulas at the screening or baseline visits were excluded
from this trial. The primary outcome of the ADAFI was at least
50% reduction of the number of draining fistulas from baseline
to week 12. The proportion of patients with closure of all drain-
ing fistulas from baseline, defined as remission, at week 12 and
week 24 was a secondary outcome.
The Perianal Disease Activity Index (PDAI),13 Crohn’s
Disease Activity Index (CDAI) and Inflammatory Bowel Disease
Questionnaire (IBDQ)14 were obtained both at baseline, as well
as at week 12 and week 24. The PDAI consists of five items,
each item graded on a 5-point Likert scale with total PDAI score
ranging from 0 to 20. The CDAI scores range from 0 to 600,
with higher scores indicating more severe disease activity. The
IBDQ is a health related quality of life questionnaire, with a
total score which ranges from 32 to 224 and is derived from
scores in four domains: bowel (10 items), systemic (five items),
emotional (12 items) and social (five items).15
Serious adverse events and other adverse events of interest
were collected throughout the study. An opportunistic infection
was defined as either an infection due to an organism which
usually does not cause disease or an unusually severe infection
by an organism that normally causes mild disease only.
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Data and statistical analysis
All analyses were performed using the modified intention to
treat (M-ITT) principle in the cohort of randomised partici-
pants who fulfilled the inclusion criteria, gave written
informed consent and in whom setons were removed accord-
ing to protocol. Additional per protocol (PP) analyses were
performed.
For the primary endpoint, patients not evaluated at the sched-
uled time points were coded as non-responders. At week 12, a
sample size of 70 evaluable study participants for M-ITT was
available. Categorical variables were described globally or per
treatment group using frequencies and percentages. Their distri-
butions were compared between treatment groups by using the
χ2 test or the Fisher exact test when necessary. Continuous vari-
ables were summarised using the median and IQR or the mean
and SD and their distributions were compared between treat-
ment groups using the Mann–Whitney test.
Frequencies of response, adverse events at weeks 12 and 24
were compared between treatment groups by using the χ2 test
or the Fisher exact test.
Results were considered significant when the p value was less
than 0.05. An α-level of 0.01 was applied for IBDQ subscales to
control for multiple testing. Data were analysed with SPSS Software
for Windows, release V.17 (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Patient flow
Enrolment of participants required more time than anticipated.
Therefore, the initial enrolment period fixed to 12 months was
twice extended to ultimately 30 months in an effort to include
the required sample size. Further prolongation of inclusion
period was financially not feasible especially due to the costs
related to production of blinded medication and patient insur-
ance, necessitating closure of the study before reaching the calcu-
lated number of patients. A total of 76 patients were enrolled in
the study. In all, 37 patients were allocated to ADA+CIP and 39
patients to ADA+PLA treatment (figure 1). Six patients, three
from each group, were excluded from analysis due to the follow-
ing reasons: four had no draining fistula at baseline and in two
patients the drain was not removed according to the protocol.
Figure 1 Study flow chart.
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Baseline characteristics
Table 1 shows demographic and clinical characteristics by treat-
ment in the ADA+CIP (n=34) or ADA+PLA (n=36) group.
Baseline characteristics were similar between the two groups,
indicative of successful randomisation. The mean age of the
patients was 36.1 years, 52.9% were male subjects and 15.7%
had a stoma in situ. In total, 24 (34%) patients were previously
exposed to infliximab. Approximately 40% of the patients were
treated with concomitant CD related medications during the
study. At baseline the mean number of draining fistula was 1.57
(SD 1.0) with a mean PDAI score of 7.53 (SD 3.03). The mean
CDAI was 155.8 (SD 85.3) indicating a mildly active (luminal)
disease with a mean IBDQ score of 160, consistent with a low
quality of life in patients with fistulising CD.
Outcomes
Table 2 shows the main endpoints of study. At week 12, ADA
+CIP was associated with a significant higher number of
patients with a closure of at least 50% of draining fistulas com-
pared with patients randomised to ADA+PLA (M-ITT: 71% vs
47%, p=0.047; PP: 75% vs 51.5%, p=0.0498) (figure 2).
Univariate analysis excluded that baseline patient characteristics
influenced fistula closure in patients receiving ciprofloxacin or
placebo (table 3). In a post hoc logistic regression analysis of the
treatment effect, we adjusted for a possible effect of the pres-
ence or non-presence of stoma, and the treatment effect stayed
significant (p=0.025). Similarly for baseline CDAI and presence
of setons at baseline, the treatment effect stayed significant
(p=0.045 and 0.046).
Remission was observed in 22 out of 34 patients (65%) on
ADA+CIP at week 12, whereas this was observed in only 12 of
36 (33%) patients on ADA+PLA (p=0.009) in an M-ITT popu-
lation. In the PP population, the p value remained highly signifi-
cant (p=0.009) with remission in 69% of patients on ADA
+CIP versus 36% on ADA+PLA.
At week 24 (12 weeks after stopping the ciprofloxacin), the
difference in fistula closure rates between the two treatment
groups was not maintained; in the M-ITT population, 21 of 34
patients (62%) and 17 of 36 patients (47%) in ADA+CIP and
ADA+PLA groups, respectively, had at least 50% reduction of
the number of draining fistula (p=0.22) (figure 2). Complete
response was observed in 18 of 34 (53%) and 12 of 36 (33%)
of patients in ADA+CIP and ADA+PLA, respectively
(p=0.098). Similar, non-significant differences between the two
groups were observed in the PP population at week 24 for both
50% and 100% reduction of number of draining fistula (data
not shown).
The median PDAI at week 12 decreased (p<0.001) compared
with baseline in both treatment arms. In ADA+CIP, the PDAI
decreased from 7.5 (2–17) at baseline to 2.0 (0–16) at week 12,
mirroring the decrease in PDAI observed in the ADA+PLA,
from 7 (2–13) to 4 (0–10) at week 12. At week 24, median
PDAI was 2 (0–17) in ADA+CIP and 3.5 (0–16) in ADA+PLA.
A statistically significant difference between the two treatment
arms was observed neither at week 12 nor at week 24.
For the CDAI analysis, patients with a stoma were excluded
for analysis. At week 12, patients treated with ADA+CIP experi-
enced a significantly higher decrease in mean CDAI compared
with ADA+PLA (p=0.005). At week 24, this difference
remained statistically significant (p=0.005). This difference in
CDAI change at week 12 and week 24 could not be attributed
to a specific decrease of one of its constituting domains of vari-
ables (data not shown).
At week 12, the mean IBDQ change in ADA+CIP was 23.2
versus 10.4 in ADA+PLA (p=0.009). At week 24, no difference
(p=0.62) between the two treatment arms could be observed
with a mean IBDQ change of 16.5 versus 12.7 in ADA+CIP
and ADA+PLA, respectively. Subdividing the IBDQ in its sub-
scales and after correcting for multiple testing, a significant dif-
ference in mean IBDQ subscale score change was observed at
week 12 for the domains of bowel symptoms and of social





Mean (SD) 34.7 (11.0) 37.3 (12.4)
Median (min–max) 31 (19–63) 37 (18–68)
Sex
Male 20 (58.8%) 17 (47.2%)
Female 14 (41.2%) 19 (52.8%)
Race
Caucasian 31 (91.2%) 33 (91.7%)
Asian 1 (2.9%) 1 (2.8%)
African 0 2 (5.6%)
Other 2 (5.9%) 0
Smoking
N (%) 12 (35.3%) 10 (27.8%)
Stoma
N (%) 3 (8.8%) 8 (22.2%)
Previous infliximab
N (%) 12 (35.2%) 12 (33.3%)
Concomitant medication N (%) 14 (41.2%) 13 (36.1%)
Prednisolon 3 (8.8%) 1 (2.8%)
Any immunosuppressant 13 (38.2%) 12 (33.3%)
Azathioprine 9 (26.5%) 9 (25%)
6-Mercaptopurine 3 (8.8%) 1 (2.8%)
Methotrexate 1 (2.9%) 2 (5.6%)
Number of draining fistulas
Mean (SD) 1.59 (1.02) 1.56 (1.00)






N (%) 8 (23.5%) 7 (19.4%)
Number of setons
1 4 (11.8%) 3 (8.3%)
>1 4 (11.8%) 4 (11.1%)
PDAI score
Mean (SD) 7.59 (3.26) 7.47 (2.83)
Median (min–max) 7.5 (2–17) 7 (2–13)
CDAI*
Mean (SD) 173.2 (96.7) 136.5 (67.1)
Median (min–max) 150.5 (32–381) 118 (15–287)
IBDQ
Mean (SD) 157.6 (34.9) 162.9 (30.0)
Median (min–max) 160 (81–213) 168 (95–209)
*CDAI was determined in patients without stoma. In the placebo and ciprofloxacin
groups, 28 and 31 patients respectively had no stoma.
CDAI, Crohn’s Disease Activity Index; IBDQ, Inflammatory Bowel Disease
Questionnaire; PDAI, Perianal Disease Activity Index.
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symptoms (p=0.007 and p=0.002, respectively) in the ADA
+CIP compared with the ADA+PLA group.
Adverse events
The adverse event rates were similar regarding frequency or
severity of adverse events observed between the two groups (see
table 4). Serious adverse events were reported in five patients,
observed in three patients in the ADA+CIP and in two patients
in the ADA+PLA treatment arm. These serious adverse events
included one case of systemic herpes simplex infection in the
ADA+PLA arm occurring 2 weeks after the first adalimumab
dose and one case of sagittal sinus thrombosis in the ADA+CIP
arm, not considered to be associated with therapy. The other
adverse events scored as serious adverse event were two exacer-
bations of CD (ADA+CIP treatment arm) and one patient hos-
pitalised for acute pain due to parastomal herniation, which
spontaneously resolved within 24 h (ADA+PLA treatment arm).
In total, 91.2% (31/34) and 94.4% (34/36) (p=0.60) of
patients in ADA+CIP and ADA+PLA arms, respectively, experi-
enced adverse events. The most frequently occurring adverse
event was infection: 19 out of 34 (55.9%) in ADA+CIP com-
pared with 22 out of 36 (61.1%) of the patients in ADA+PLA
experienced an infectious adverse event. The majority of these
constituted of upper respiratory tract infections (50.0% and
Table 2 Main endpoints
Week 12 Week 24
Ciprofloxacin Placebo p Value Ciprofloxacin Placebo p Value
n=34 n=36 n=34 n=36
50% reduction in number of fistulas
n 24 17 21 17
% (95% CI) 71% (54 to 87) 47% (30 to 64) 0.047 62% (45 to 79) 47% (30 to 64) 0.22
100% reduction in number of fistulas
n 22 12 18 12
% (95% CI) 65% (48 to 82) 33% (17 to 50) 0.009 53% (35 to 71) 33% (17 to 50) 0.098
PDAI, median (range)
Score 2 (0–16) 4 (0–10) 2 (0–17) 3.5 (0–16)
Δ Compared with week 0 5 (−1–9) 3 (−1–10) 0.16 4 (−1–9) 3 (−6–12) 0.32
PDAI, median (IQR)
Score 2 (1–5) 4 (2–5) 2 (0–17) 3.5 (0–16)
Δ Compared with week 0 5 (3.0–6.0) 3 (1.25–5.75) 0.16 4 (2–7) 3 (1–6.5) 0.32
CDAI, mean (95% CI) n=28 n=25 n=25 n=22
Score 105 (74 to 136) 113 (82 to 145) 120 (78 to 161) 122 (79 to 166)
Δ Compared with week 0 74 (48 to 101) 23 (6 to 40) 0.002 67 (30 to 104) 8 (−18 to 33) 0.01
IBDQ, mean (95% CI) n=30 n=30 n=30 n=27
Score 181 (172 to 191) 173 (161 to 186) 174 (160 to 189) 178 (166 to 191)
Δ Compared with week 0 23 (16 to 30) 10 (4 to 17) 0.009 17 (6 to 27) 13 (1 to 25) 0.69
IBDQ bowel, mean (95% CI)
Score 57 (55 to 60) 54 (51 to 57) 53 (49 to 58) 56 (53 to 59)
Δ Compared with week 0 9 (6 to 12) 4 (2 to 6) 0.007 5 (1 to 9) 6 (2 to 9) 0.77
IBDQ systemic, mean (95% CI)
Score 25 (23 to 27) 24 (22 to 27) 25 (22 to 27) 26 (23 to 29)
Δ Compared with week 0 4 (3 to 6) 2 (0 to 4) 0.03 4 (1 to 6) 3 (0 to 6) 0.71
IBDQ emotion, mean (95% CI)
Score 68 (64 to 73) 65 (60 to 71) 67 (61 to 73) 66 (60 to 72)
Δ Compared with week 0 5 (2 to 8) 3 (0 to 7) 0.45 4 (0 to 7) 3 (−2 to 9) 0.9
IBDQ social, mean (95% CI)
Score 30 (38 to 32) 30 (27 to 32) 29 (26 to 32) 30 (27 to 32)
Δ Compared with week 0 5 (3 to 7) 1 (0 to 3) 0.002 4 (1 to 7) 1 (−1 to 4) 0.12
CDAI, Crohn’s Disease Activity Index; IBDQ, Inflammatory Bowel Disease Questionnaire; PDAI, Perianal Disease Activity Index.
Figure 2 Percentage of patients with response (≥50% closure of
draining fistulas from baseline) and remission (100% closure of
draining fistulas) at week 12 (primary endpoint) and at week 24 in the
two treatment arms.
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55.6% of patients, respectively). Opportunistic infections were
reported in 5/34 (14.7%) in ADA+CIP versus 4/36 (11.1%)
patients treated with ADA+PLA. All of these opportunistic
infections but one were mild adverse events, including skin
related ailments like vaginal candidiasis or onychomycosis.
The occurrence of three perianal abscess was documented:
one in the ADA+CIP treatment arm and two in the ADA+PLA
treatment.
DISCUSSION
This is the first trial demonstrating a superior effect of combin-
ation therapy of adalimumab with ciprofloxacin compared with
adalimumab monotherapy to achieve fistula closure in CD
related perianal fistulising disease. A placebo controlled study,
evaluating combination therapy with infliximab and ciprofloxa-
cin versus infliximab alone was unable to show a difference in
response rate of perianal fistulas in CD, ascribed to the small
sample size.11 Interestingly, although a clear trend to a higher
remission rate in patients treated with combination therapy is
observed at week 24, no significant difference for the primary
endpoint was observed 12 weeks after discontinuation of cipro-
floxacin. This was solely due to loss of response in three patients
randomised to the combination treatment group, whereas the
number of patients in the adalimumab monotherapy group who
had reached the primary endpoint at week 12 remained stable at
week 24, which is consistent with data from the CHARM trial,
demonstrating long term maintenance of fistula closure.10
Univariate analysis showed that outcome was not influenced
by any of the patient characteristics. Although, due to the small
number of patients in each subgroup, caution should be exer-
cised in further interpreting this analysis, it is interesting to note
that previous treatment with infliximab did not impair fistula
closure with adalimumab. This is in agreement with data from
the CHOICE trial, an open-label study evaluating efficacy in
CD patients failing on infliximab treatment, in which complete
fistula closure was observed in 39% of patients.16 Because of the
(not significant) imbalance between the two groups regarding
the presence of stoma and baseline CDAI, a post hoc analysis
was performed. The treatment effect after correction for these
factors remained significant.
Although the overall, mean CDAI at baseline reflected an
almost quiescent luminal disease status of the randomised
patients, the reduction of mean CDAI at week 12 was statistic-
ally significantly larger in the combination treatment group com-
pared with adalimumab alone. This is in line with results from a
randomised trial showing effectiveness of ciprofloxacin in the
treatment in moderately active CD.17 A recently published
cohort study,18 evaluating the use of autologous bone derived
mesenchymal stromal cells in the treatment of fistulising CD
after administration of broad-spectrum antibiotics for 2 weeks
immediately prior to the first injection procedure, also demon-
strated a significant decrease of CDAI after treatment. However,
this was largely due to an increase of general well-being, which
is one of the eight variables constituting the CDAI. In our
patient group, however, the decrease of CDAI could not be
attributed to selective decrease of one of its subdomains.
It has been shown that patients in symptomatic remission
usually have an IBDQ of at least 170.19 20 Although the mean
CDAI in our patient group was only slightly higher than 150,
the mean IBDQ at baseline was noticeably below 170 points,
which suggests that particularly perianal fistulas in CD contrib-
ute negatively to quality of life. To corroborate this observation,
12 weeks of combination therapy with adalimumab and cipro-
floxacin resulted in a more marked increase of IBDQ compared
with adalimumab monotherapy, with an absolute increase of 23
points, being defined as clinically relevant.20
Although the number of patients included in this trial is too
small to draw firm conclusions with respect to adverse events
associated with combination therapy, it is reassuring that the
Table 3 Univariate analysis
Primary endpoint
Yes No p Value
Sex
Male 21 (56.8%) 16 (43.2%) 0.74
Female 20 (60.6%) 13 (39.4%)
Race
Caucasian 36 (56.3%) 28 (43.8%) 0.39
Other 5 (83.3%) 1 (16.7%)
Seton
Yes 9 (60%) 6 (40%) 0.90
No 32 (58.2%) 23 (41.8%)
Stoma
Yes 8 (72.7%) 3 (27.3%) 0.30
No 33 (55.9%) 26 (44.1%)
Tobacco
Yes 12 (54.5%) 10 (45.5%) 0.64
No 29 (60.4%) 19 (39.6%)
Previous IFX
Yes 15 (62.5%) 9 (37.5%) 0.63
No 26 (56.5%) 20 (43.5%)
Corticosteroids
Yes 2 (50%) 2 (50%) 0.72
No 39 (59.1%) 27 (40.9%)
AZA/6MP/MTX
Yes 12 (48.0%) 13 (52.0%) 0.18
No 29 (46.4%) 16 (35.6%)
IFX, infliximab; AZA, azathioprine; 6MP, 6-mercaptopurine, MTX, methotrexate.
Table 4 Summary of safety and occurrence of adverse events
Ciprofloxacin Placebo
(N=34) (N=36) p Value
Serious AE 3 (8.8%) 3 (8.3%) 1.00
Any AE 31 (91.2%) 34 (94.4%) 0.60
Most common AE
URTI 17 (50.0%) 20 (55.6%) 0.64
Fatigue 10 (29.4%) 12 (33.3%) 0.72
Headache 10 (29.4%) 6 (16.7%) 0.20
Nausea 7 (20.6%) 3 (8.3%) 0.18
Infection 19 (55.9%) 22 (61.1%) 0.66
Serious infectious AE 0 (0%) 1 (2.8%)* 1.00
Opportunistic infection 5 (14.7%)† 4 (11.1%)‡ 0.73
Perianal abscess 1 (2.9%) 2 (5.6%) 1.00
Thromboembolic AE 1 (2.9%)§ 0 0.49
Worsening Crohn’s disease 3 (8.8%) 3 (8.3%) 1.00
*Systemic herpes simplex infection.
‡Four events in four patients: two events of mucocutaneous mycosal infection, one
event of systemic herpes infection, one event of HPV related warts.
†Seven events in five patients: five mucocutaneous mycosal infections, one event of
herpes labialis, one event of enlargement of a pre-existing genital human
papillomavirus wart.
§Sagittal sinus thrombosis.
AE, adverse event; URTI, upper respiratory tract infection.
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rate of adverse events in the combination therapy group is not
increased. This might especially be of importance regarding the
occurrence of non-bacterial opportunistic infections, which
might be associated with use of antibiotics. Additionally, infec-
tions with Clostridium difficile were not observed. High rates of
perianal abscess formation have been described after treatment
with anti-tumour necrosis factor (TNF) and it is therefore
advised to perform additional imaging (magnetic resonance
imaging (MRI) or endo-anal ultrasound (EUS)) prior to start of
anti-TNF therapy and to insert drains in perianal fistula tracts to
optimise drainage and prevent the premature closure of the
fistula. Interestingly, in this study abscess related adverse events
were low, even in the absence of perianal drains at baseline or
without prior MRI, suggesting that a well-executed clinical
examination might be equivalent in the detection of insufficient
drainage. Moreover, no difference in abscess related adverse
events was detected between combination and adalimumab
monotherapy, arguing against a role for ciprofloxacin in the pre-
vention of abscesses. However, a possible significant difference
might have been obscured by the low number of abscesses
observed in the adalimumab alone group.
Although the inclusion period was prolonged with 16 months
in an attempt to reach the calculated sample size, fewer patients
than anticipated were included. Although the overestimation of
beneficial effect is a well-recognised problem in randomised
controlled trials stopped early for overt efficacy,21 the situation
for trials stopped for economic reasons is more elusive. As this
trial was stopped solely for economical reasons, without per-
forming an interim analysis, the results in this randomised con-
trolled trial are unlikely to be attributed to a possible
underpowered study. Moreover, the result of a small randomised
controlled trial comparing combination therapy of infliximab
and ciprofloxacin with infliximab monotherapy was already sug-
gestive for a benefit for combination therapy,11 supporting our
current findings. As the design of both studies is comparable, a
meta-analysis of the effect of antibiotics on top of anti-TNF
treatment would be of high interest.
In this study, imaging with MRI or EUS was not performed at
baseline nor at a later time point and the assessment of perianal
fistulas or abscesses was solely based on dedicated clinical inves-
tigation. As it has been described that clinical judgment of
fistula closure might not correlate with true fistula healing as
evaluated with ultrasound and MRI,22–24 this might result in an
overestimation of the treatment effect. However, a recent study
described that the median lag between radiological healing and
clinical remission is 12 months, thereby underestimating the
benefit of anti-TNF therapy in the short term. Moreover, after
stopping anti-TNF treatment, the recurrence of draining fistulas
was observed even by radiology determined healed fistula tracts,
questioning the additive clinical value of MRI to clinical investi-
gation.25 The same conclusion can be drawn from the study of
Karmiris et al26 describing that MRI underestimates the clinical
response to long term anti-TNF, thereby arguing against suffi-
cient specificity of MRI to detect fistula healing in long term
follow-up.
Finally, although a better outcome was observed with combin-
ation therapy compared with adalimumab monotherapy, this dif-
ference disappeared after administration of ciprofloxacin was
discontinued. We speculate that this might partially be due to
the small number of patients of included in the trial, as the loss
of significance was solely due to loss of response in some
patients in the combination treatment group. On the other
hand, as long term treatment with ciprofloxacin for antibiotic-
dependent chronic pouchitis is an established treatment
option27 without occurrence of C difficile colonisation,28 it is
tempting to speculate that long term combination treatment of
adalimumab with ciprofloxacin results in a more consistent
closure of perianal fistulas. Given the fact that the effect of
ciprofloxacin is lost after its discontinuation, the better response
rate might be at least partially related to a better control of the
residual microflora which potentially remains present in the
medically closed fistula tract. This hypothesis is corroborated by
recent in vitro data revealing that bacterial wall components are
involved in fistula pathogenesis, suggesting that antibiotics might
contribute to fistula closure.29
In conclusion, the ADAFI trial clearly shows that combination
therapy of adalimumab with ciprofloxacin is associated with a
higher fistula closure rate with a clinically significant impact on
HRQoF, IBDQ and CDAI compared with adalimumab mono-
therapy over a 3-month period. However, after discontinuation
of antibiotic therapy, the beneficial effect of initial coadministra-
tion is not maintained.
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